EBMT 2025 | MRD-driven treatment in AML and its role in stem cell transplantation
In this video, Francesco Buccisano, MD, University of Rome Tor Vergata, Rome, Italy, briefly comments on the role of measurable residual disease (MRD) in acute myeloid leukemia (AML) treatment, stating that MRD is becoming a fundamental biomarker to assess treatment response and that its persistence is a poor prognosticator, leading to consideration for allogeneic stem cell transplantation (alloSCT). This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, MRD, measurable residual disease, is becoming a fundamental biomarker to assess the quality of response to intensive chemotherapy and even to low-dose chemotherapy, but this is another story. And we are integrating this biomarker more and more in all the clinical trials that are treating younger patients affected with AML. The persistence of measurable residual disease is a poor prognosticator, so we consider MRD positivity as a key element to address the patient toward an allogeneic stem cell procedure...
Well, MRD, measurable residual disease, is becoming a fundamental biomarker to assess the quality of response to intensive chemotherapy and even to low-dose chemotherapy, but this is another story. And we are integrating this biomarker more and more in all the clinical trials that are treating younger patients affected with AML. The persistence of measurable residual disease is a poor prognosticator, so we consider MRD positivity as a key element to address the patient toward an allogeneic stem cell procedure.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Speakers bureau: Jazz, Delbert, Servier, Novartis, Menarini.
